Fig. 1

eMSCs inhibited the viability of EC patient-derived organoids. A Bright field images of EC organoids were taken from day 1 to day 6 after establishment. Original magnification, 4 × ; Scale bar, 400 μm. B Bright field images of EC organoids at Passage 1, Passage 5, and Passage 10. Original magnification, 4 × ; Scale bar, 400 μm. C Immunofluorescence staining images for DAPI, Ki67, and cytokeratin 7 (CK7) in EC organoids. Original magnification, 20 × ; Scale bar, 80 μm. D H&E and IHC staining images for Ki67, ERα, and PR in EC tissues and organoids. Original magnification, 20 × ; Scale bar, 80 μm. E eMSCs had the strongest inhibitory effect on the viability of EC organoids. EC organoids were treated with NM or CM derived from AD-MSCs, UC-MSCs, or eMSCs respectively for 96 h before three-dimensional cell viability assay. Three organoid lines derived from three patients with well-differentiated endometrial endometrioid cancer were used. Each EC organoid line was tested independently and was repeated three times in the same condition with independent analysis. NM, normal medium; CM, conditioned medium; Data were analyzed by ratio t-test (E). ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001